Single-course in vivo base editing therapy proven to lower cholesterol
Drug Discovery World
NOVEMBER 14, 2023
FH is one of the most common genetic conditions, affecting around one in 300 people globally. It is caused by a single gene mutation that impairs the body’s ability to mediate LDL cholesterol. Since the mutation only affects a single gene, it makes it a prime candidate for genome editing treatments.
Let's personalize your content